AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04951271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution focused approach
Description: The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
Study NCT02378194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks, once daily oral administration
Study NCT03725696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semen Analysis
Description: Sperm counts will be determined by semen analysis.
Study NCT03725696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal panel
Description: Blood test for LH, FSH, testosterone, and estradiol
Study NCT03725696 — intervention group
Intervention type: PROCEDURE
Intervention: RYGB Gastric Bypass
Description: Roux-en-Y Gastric Bypass
Study NCT03725696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF Survey
Description: International Index of Erectile Function is a validated 5-question survey examining sexual health in men
Study NCT01963403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE 30mcg/LNG 150mcg
Description: 1 pill per day; daily during study participation (up to 84 days)
Study NCT01963403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill per day; daily during study participation (up to 84 days)
Study NCT04087694 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdecompression
Description: comparative surgical treatment
Study NCT00589914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RISPERDAL CONSTA
Description: RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
Study NCT01385800 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection 1 x 8 administrations 2 weeks apart
Study NCT00589914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
Study NCT03032757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: 240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
Study NCT01854866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-packaging microparticles
Description: Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
Study NCT02590198 — intervention group
Intervention type: OTHER
Intervention: ANAES algorithm
Description: care as recommended by ANAES, with ANAES algorithm
Study NCT02590198 — intervention group
Intervention type: OTHER
Intervention: PCT algorithm
Description: care based on PCT algorithm
Study NCT03653897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID-Capsule- Active
Description: A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
Study NCT02378194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-003 (800mg/day)
Description: 24 weeks, once daily oral administration
Study NCT02378194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD-003 (1600mg/day)
Description: 24 weeks, once daily oral administration
Study NCT00701298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: Given SC
Study NCT00701298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: Given IV
Study NCT00701298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00701298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00701298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02865889 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy in Gynecologic Oncologic Indications
Study NCT02865889 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional surgery (abdominal radical surgery)
Study NCT01567592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2
Study NCT01263392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheterization
Description: Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
Study NCT03784846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training
Description: MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
Study NCT03784846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
Study NCT04006210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ND0612 Solution for SC infusion
Description: Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
Study NCT04006210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ND0612 Solution for SC infusion
Description: Levodopa/Carbidopa (LD/CD) solution administered SC via infusion pump
Study NCT04006210 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SC infusion
Description: Placebo solution administered SC via infusion pump
Study NCT04006210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg
Study NCT04006210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg
Study NCT04006210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral IR-LD/CD
Description: Encapsulated LD/CD 100mg/25mg
Study NCT04006210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Oral IR-LD/CD
Description: Encapsulated Placebo for LD/CD 100mg/25mg
Study NCT04006210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oral IR-LD/CD
Description: Encapsulated Placebo for LD/CD 100mg/25mg
Study NCT02614040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered
Study NCT02614040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study NCT03054350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Daily oral dose
Study NCT03054350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose
Study NCT02470143 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bike application arm
Description: The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
Study NCT02116114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
Study NCT01654159 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Monofocal IOL
Description: Monofocal Intraocular lens will be implanted
Study NCT01654159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Description: Multifocal IOL will be implanted
Study NCT01654159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toric IOL
Description: Toric IOLS will be implanted
Study NCT02419131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Headache Therapy
Description: A standard, manualized behavioral intervention for primary headache disorders
Study NCT02419131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A gold-standard treatment for PTSD, called Cognitive Processing Therapy
Study NCT02419131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual, receiving standard care for PTHA
Study NCT03060512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.
Study NCT03060512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Movantik
Description: Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours.
Study NCT02612701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
Study NCT02612701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (nicotine free e-liquid)
Description: Subjects will smoke nicotine free e-liquid with an e-cigarette.
Study NCT02612701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (low nicotine e-liquid)
Description: Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
Study NCT02612701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarettes (high nicotine e-liquid)
Description: Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
Study NCT03264105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
Study NCT03264105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite Nanofiber reinforced flowable composite
Description: retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
Study NCT03264105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional resin-based flowable composite
Description: retention rate evaluation of conventional resin-based flowable composite
Study NCT01488539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAIR/NT treatment
Description: STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
Study NCT03264105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional resin-based flowable composite
Description: retention rate evaluation of conventional resin-based flowable composite
Study NCT02093429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: INCB047986 will be supplied as tablets.
Study NCT01488539 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
Study NCT03653897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: Subjects will wear an ID-Reader
Study NCT02426255 — intervention group
Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
Study NCT00672087 — intervention group
Intervention type: GENETIC
Intervention: Genomic and proteomic biomarker discovery
Description: Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
Study NCT02370537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova® (omega-3 carboxylic acids)
Description: 4 g (administered orally as 4 x 1 g capsules)
Study NCT02370537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor® (omega-3-acid ethyl esters)
Description: 4 g (administered orally as 4 x 1 g capsules)
Study NCT03610581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV16
Description: Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
Study NCT03610581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.HPV18
Description: Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
Study NCT03610581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HPV16/18
Description: Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
Study NCT03610581 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matched placebo as a solution for intramuscular injection.
Study NCT04688762 — intervention group
Intervention type: OTHER
Intervention: e-consult application (tool)
Description: A numeric application used as a support in consultation to explain the surgical management of the patient.
Study NCT03094650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindMotion PRO
Description: Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
Study NCT00904618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-SECUR - 'Hammock' technique
Description: The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
Study NCT00904618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-SECUR - 'U-Method'
Description: The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
Study NCT00904618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).
Description: Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
Study NCT00591968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite Titan portable ultrasound coupled with email telediagnosis
Description: Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience.
Study NCT02138474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacticum acidum homaccord
Description: Homeopathic remedy, made using sucrose pillules
Study NCT02138474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unmedicated sucrose pillules
Study NCT02615860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical 85% trichloroacetic acid (TCA)
Description: In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
Study NCT02615860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical electrocautery (ECA)
Description: In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
Study NCT02441140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culdocentesis
Description: A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
Study NCT02441140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Swab
Description: . A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
Study NCT02441140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromopertubation
Description: Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
Study NCT02441140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Intravenous blood collection will be drawn from an IV
Study NCT02441140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
Study NCT04083313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technique used for closing the appendiceal stump
Description: In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
Study NCT01261130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Na-GST-1/Alhydrogel
Description: 3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
Study NCT01261130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg Na-GST-1/Alhydrogel
Description: 3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals